Gain Therapeutics (GANX) Common Equity (2020 - 2025)
Historic Common Equity for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $5.9 million.
- Gain Therapeutics' Common Equity fell 3367.18% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year decrease of 3367.18%. This contributed to the annual value of $7.3 million for FY2024, which is 4164.86% down from last year.
- As of Q3 2025, Gain Therapeutics' Common Equity stood at $5.9 million, which was down 3367.18% from $3.7 million recorded in Q2 2025.
- In the past 5 years, Gain Therapeutics' Common Equity ranged from a high of $44.5 million in Q1 2021 and a low of $3.7 million during Q2 2025
- Its 5-year average for Common Equity is $18.8 million, with a median of $12.6 million in 2023.
- Its Common Equity has fluctuated over the past 5 years, first soared by 46139.32% in 2021, then plummeted by 6863.7% in 2025.
- Over the past 5 years, Gain Therapeutics' Common Equity (Quarter) stood at $34.8 million in 2021, then plummeted by 45.78% to $18.9 million in 2022, then crashed by 33.38% to $12.6 million in 2023, then plummeted by 41.65% to $7.3 million in 2024, then fell by 19.49% to $5.9 million in 2025.
- Its Common Equity stands at $5.9 million for Q3 2025, versus $3.7 million for Q2 2025 and $5.8 million for Q1 2025.